{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:59:13Z","timestamp":1761947953215},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,3,12]],"date-time":"2014-03-12T00:00:00Z","timestamp":1394582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,3,12]],"date-time":"2014-03-12T00:00:00Z","timestamp":1394582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s10637-014-0078-5","type":"journal-article","created":{"date-parts":[[2014,3,11]],"date-time":"2014-03-11T04:41:41Z","timestamp":1394512901000},"page":"729-738","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Randomized phase II trial of sorafenib alone or in combination with carboplatin\/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer"],"prefix":"10.1007","volume":"32","author":[{"given":"Anita","family":"Schwandt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian E.","family":"von Gruenigen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Wenham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Frasure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingfu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afshin","family":"Dowlati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Waggoner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,12]]},"reference":[{"key":"78_CR1","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1093\/annonc\/mdp233","volume":"20","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol Off J Eur Soc Med Oncol 20:1842\u20131847. doi:10.1093\/annonc\/mdp233","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"78_CR2","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol Off J Am Soc Clin Oncol 30:2039\u20132045. doi:10.1200\/jco.2012.42.0505","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"78_CR3","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm S et al (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5:835\u2013844. doi:10.1038\/nrd2130","journal-title":"Nat Rev Drug Discov"},{"key":"78_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125\u2013134. doi:10.1056\/NEJMoa060655","journal-title":"N Engl J Med"},{"key":"78_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378\u2013390. doi:10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"key":"78_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1089\/dna.1993.12.623","volume":"12","author":"CH Chien","year":"1993","unstructured":"Chien CH, Chow SN (1993) Point mutation of the ras oncogene in human ovarian cancer. DNA Cell Biol 12:623\u2013627","journal-title":"DNA Cell Biol"},{"key":"78_CR7","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1054\/bjoc.2001.2139","volume":"85","author":"F McPhillips","year":"2001","unstructured":"McPhillips F et al (2001) Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br J Cancer 85:1753\u20131758. doi:10.1054\/bjoc.2001.2139","journal-title":"Br J Cancer"},{"key":"78_CR8","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949\u2013954. doi:10.1038\/nature00766","journal-title":"Nature"},{"key":"78_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/sj.bjc.6605514","volume":"102","author":"JM Lee","year":"2010","unstructured":"Lee JM et al (2010) Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br J Cancer 102:495\u2013499. doi:10.1038\/sj.bjc.6605514","journal-title":"Br J Cancer"},{"key":"78_CR10","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/IGC.0b013e3181e273a8","volume":"20","author":"SA Welch","year":"2010","unstructured":"Welch SA et al (2010) Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 20:787\u2013793. doi:10.1111\/IGC.0b013e3181e273a8","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"78_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ygyno.2011.08.033","volume":"123","author":"R Ramasubbaiah","year":"2011","unstructured":"Ramasubbaiah R et al (2011) Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I\/II study of the Hoosier Oncology Group. Gynecol Oncol 123:499\u2013504. doi:10.1016\/j.ygyno.2011.08.033","journal-title":"Gynecol Oncol"},{"key":"78_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1200\/JCO.2009.26.7856","volume":"29","author":"D Matei","year":"2011","unstructured":"Matei D et al (2011) Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol Off J Am Soc Clin Oncol 29:69\u201375. doi:10.1200\/JCO.2009.26.7856","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"78_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"78_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310","journal-title":"Control Clin Trials"},{"key":"78_CR15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1214\/ss\/1009213286","volume":"16","author":"LD Brown","year":"2001","unstructured":"Brown LD et al (2001) Interval estimation for a binomial proportion - Comment - Rejoinder. Stat Sci 16:101\u2013133","journal-title":"Stat Sci"},{"key":"78_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"78_CR17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/107327480901600110","volume":"16","author":"CB Marquez","year":"2009","unstructured":"Marquez CB et al (2009) Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene. Cancer Control 16:66\u201369","journal-title":"Cancer Control"},{"key":"78_CR18","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1200\/JCO.1998.16.4.1494","volume":"16","author":"PG Rose","year":"1998","unstructured":"Rose PG, Fusco N, Fluellen L, Rodriguez M (1998) Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 16:1494\u20131497","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"78_CR19","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1093\/annonc\/mds027","volume":"23","author":"JJ Wheler","year":"2012","unstructured":"Wheler JJ et al (2012) Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol Off J Eur Soc Med Oncol 23:1963\u20131967. doi:10.1093\/annonc\/mds027","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"78_CR20","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1200\/JCO.2009.23.4823","volume":"27","author":"JP Arnault","year":"2009","unstructured":"Arnault JP et al (2009) Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol Off J Am Soc Clin Oncol 27:e59\u2013e61. doi:10.1200\/JCO.2009.23.4823","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"78_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1158\/1078-0432.CCR-11-1344","volume":"18","author":"JP Arnault","year":"2012","unstructured":"Arnault JP et al (2012) Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res Off J Am Assoc Cancer Res 18:263\u2013272. doi:10.1158\/1078-0432.CCR-11-1344","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"78_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3816\/CGC.2009.n.003","volume":"7","author":"Z Dubauskas","year":"2009","unstructured":"Dubauskas Z et al (2009) Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 7:20\u201323. doi:10.3816\/CGC.2009.n.003","journal-title":"Clin Genitourin Cancer"},{"key":"78_CR23","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/archderm.144.6.779","volume":"144","author":"DS Hong","year":"2008","unstructured":"Hong DS et al (2008) Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol 144:779\u2013782. doi:10.1001\/archderm.144.6.779","journal-title":"Arch Dermatol"},{"key":"78_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ygyno.2011.06.019","volume":"123","author":"L Bodnar","year":"2011","unstructured":"Bodnar L, G\u00f3rnas M, Szczylik C (2011) Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. Gynecol Oncol 123:33\u201336. doi:10.1016\/j.ygyno.2011.06.019","journal-title":"Gynecol Oncol"},{"key":"78_CR25","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473\u20132483. doi:10.1056\/NEJMoa1104390","journal-title":"N Engl J Med"},{"key":"78_CR26","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484\u20132496. doi:10.1056\/NEJMoa1103799","journal-title":"N Engl J Med"},{"key":"78_CR27","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S1470-2045(12)70567-3","volume":"14","author":"D Stark","year":"2013","unstructured":"Stark D et al (2013) Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol 14:236\u2013243. doi:10.1016\/S1470-2045(12)70567-3","journal-title":"Lancet Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0078-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-014-0078-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0078-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0078-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:50:10Z","timestamp":1678510210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-014-0078-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,12]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["78"],"URL":"https:\/\/doi.org\/10.1007\/s10637-014-0078-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,12]]},"assertion":[{"value":"2 January 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}